Reference List for Predictive Testing in RA

1. Centers for Disease Control and Prevention. Rheumatoid Arthritis (RA). 2020; https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html. Accessed July 21, 2020.

2. Minichiello E, Semerano L, Boissier MC. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. *Joint Bone Spine.* 2016;83(6):625-630.

3. Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014. *Ann Rheum Dis.* 2020;79(4):440-444

4. UK National Health Service. Diagnosis: rheumatoid arthritis. 2019; https://www.nhs.uk/conditions/rheumatoid-arthritis/diagnosis/. Accessed July 20, 2020.

5. Batko B, Urbanski K, Swierkot J, et al. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. *Clin Rheumatol.* 2019;38(9):2473-2481.

6. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). *Ann Rheum Dis.* 2014;73(1):62-68.

7. van den Hoek J, Boshuizen HC, Roorda LD, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. *Rheumatology International*. 2017;37(4):487-493.

8. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis.* 2020.

9. Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. *BMC Rheumatol.* 2019;3:42.

10. Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis & Rheumatology.* 2016;68(1):1-26.

11. Mellors T, Withers JB, Ameli A, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. Network and Systems Medicine 2020;3(1):91-104.

12. Bergman MJ, et al. Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis. Rheumatology and Therapy. 2020 Dec;7(4):775-792.

13. Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF- inhibitors in rheumatoid arthritis: the negative impact of TNFi cycling and the need for a personalized medicine approach to identify primary non- responders. Clin Rheumatol. 2019;38(11):2967-2976.

14. Pokharel G, Deardon R, Barnabe C, et al. Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. ACR Open Rheumatol. 2019;1(8):471-9.

15. Clinicaltrials.gov. Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study (CERTAIN) [NCT01625650]. 2018; https://clinicaltrials.gov/ct2/show/NCT01625650. Accessed February 25, 2020.

16. Corrona. CERTAIN Rheumatoid Arthritis Registry. https://www.corrona. org/certain-rheumatoid-arthritis-registry. Accessed February 25, 2020.

17. Felson DT, LaValley MP. The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. Arthritis Res Ther 2014; 16(1): 101.

18. Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. *Arthritis Care Res (Hoboken).* 2014;66(11):1604-1611.

19. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181(11):787-96.

20. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54(11):3399-407.

21. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52.

22. Bonafede MMK, Curtis JR, McMorrow D, Mahajan P, Chen CI (2016) Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. Clin Outcomes Res 8:707–715.

23. Kavanaugh A, Van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guérette B, Kupper H, Smolen JS (2018) Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis 77:289–292.

24. Grabner M, Boytsov NN, Huang Q, Zhang X, Yan T, Curtis JR (2017) Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: A retrospective claims analysis. Arthritis Res Ther 19:1–12.

25. Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. *Ann Rheum Dis.* 2015;74(2):430-436.

26. Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. *J Med Econ.* 2017;20(5):464-473.

27. Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. *Adv Ther.* 2017;34(11):2422-2435.

28. Wei W, Knapp K, Wang L, et al. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. *Adv Ther.* 2017;34(8):1936-1952.

29. McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA (2011) Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis. J Rheumatol 38:2141–2149.

30. Aco Acosta-Herrera M, González-Serna D, Martín J (2019) The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. J Clin Med 8:826.

31. Institute for Clinical and Economic Review (ICER). Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value. 2017; https://icerreview.org/wpcontent/uploads/2016/08/NE_CEPAC_RA_Evidence_Report_FINAL_040717.pdf

32. Pappas D, et al. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: Results from a decision impact survey. Rheumatology International. 2020. *In press.*

33. Xeljanz® (tofacitinib) [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf. Accessed July 31,2020.

34. Orencia® (abatacept) [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125118s171lbl.pdf Accessed July 31, 2020.

35. Actemra® (Tocilizumab) [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125276s107_125472s018lbl.pdf. Accessed July 31, 2020.

36. Kevzara® (sarilumab) [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761037s001lbl.pdf. Accessed July 31, 2020.

37. Rinvoq® (upadacitinib) [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf. Accessed July 31, 2020.

38. Rituxan® (rituximab) [Prescribing Information].

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Accessed July 31, 2020.

39. Olumiant® (baricitinib) [Prescribing Information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf. Accessed July 31, 2020.

40. Withers, Johanna B et al. Longitudinal analysis of rheumatoid arthritis patients with a molecular signature of inadequate response to tumor necrosis factor inhibitor therapies. Manuscript for Publication. 2020.

41. Kearsley-Fleet, L., Davies, R., De Cock, D., Watson, K. D., Lunt, M., Buch, M. H., ... & Hyrich, K. L. (2018). Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Annals of the rheumatic diseases*, *77*(10), 1405-1412.

42. Cohen S, Wells AF, Curtis JR, Dhar R, Mellors T, Zhang L, Withers JB, Jones A, Ghiassian SD, Wang M, Connolly-Strong E, Rapisardo S, Gatalica Z, Pappas DA, Kremer JM, Saleh A, Akmaev VR. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study. Rheumatol Ther. 2021 Sep;8(3):1159-1176.

43. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939.

44. Senbel E, Durand F, Roux B, Badaoui FZ, Fautrel B. Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent. Rheumatol Ther. 2021 Jun;8(2):921-935. doi: 10.1007/s40744-021-00311-1. Epub 2021 May 3. PMID: 33939171; PMCID: PMC8217392.